Want to see AKBA full AI Analyst Report?
AKBA Stock Chart & Stats
$0.96
$0.06(4.92%)
At close: 4:00 PM EDT
$0.96
$0.06(4.92%)
Day’s Range― - ―
52-Week Range$0.54 - $2.23
Previous Close$1.28
Volume1.86M
Average Volume (3M)8.07M
Market Cap
$195.78M
Enterprise Value$360.90M
Total Cash (Recent Filing)$155.55M
Total Debt (Recent Filing)$53.96M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding277,106,230
10 Day Avg. Volume10,120,873
30 Day Avg. Volume8,066,554
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)12.70
Price to Sales (P/S)1.75
P/FCF Ratio6.09
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda-19.68
Forecast
1Y Price Target
$3.90Price Target Upside306.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$197.85M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin near 79% indicates favorable product-level economics and leaves meaningful capacity to support commercial investment. This provides a stronger foundation for future operating leverage, although the benefit depends on Akebia converting gross profit into sustainable operating profitability.
Improved Cash GenerationThe shift to positive operating and free cash flow is a meaningful improvement in financial durability because it demonstrates recent cash generation alongside accounting losses. If maintained, this could reduce reliance on external capital and provide greater flexibility to fund ongoing commercial and pipeline activities.
Commercial Product And PipelineAkebia has an established commercial product rather than relying solely on preclinical or development-stage assets, while its renal and cardiometabolic pipeline offers additional avenues for growth. This combination can support business continuity and broaden future revenue opportunities if programs progress.
Bears Say
Persistent Operating LossesThe return to negative EBIT and EBITDA, combined with a recent revenue decline, shows that improved gross profitability has not yet translated into consistent earnings power. Continued operating losses can constrain reinvestment and make future financial performance more dependent on successful revenue stabilization.
Fragile Balance SheetDebt exceeding equity and the history of negative equity indicate limited balance-sheet resilience relative to the company’s uneven profitability. Although leverage improved from 2025, financial flexibility remains sensitive to weaker operations, making capital allocation and funding decisions more consequential.
Nasdaq Listing Compliance RiskThe Nasdaq deficiency creates a material corporate and financing overhang because failure to regain compliance could lead to delisting or require a reverse stock split. The extended compliance window provides time to respond, but the outcome remains uncertain and could disrupt market access.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.54 and its highest was $2.23 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $195.78M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.042 by $0.012.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.04.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 277,106,230 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.042. Following the earnings report the stock price went down -26.047%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.90 (306.25% Upside)
$3.90 (306.25% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 75%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 270.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.38%
12-Months-Change
Fundamentals
Return on Equity
-93.74%
Trailing 12-Months
Asset Growth
1.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$3.90
▲(306.25% Upside)
Technical Analysis
Protalix
―
Eledon Pharmaceuticals
―
Equillium
―
Unicycive Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
2.89% Insiders
8.58% Mutual Funds
0.39% Other Institutional Investors
76.90% Public Companies and
Individual Investors